association

Full identifier: http://purl.org/np/RAsJA-5zi6dJjp4usxaEBKAWNaMX5Gm4A0SaEJ2tXX3Bc#association

Assigned to 1 class:

Minted in Nanopublication

 RAsJA-5zi6 comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAsJA-5zi6...#association association https://w3id.org/biolink/vocab/has_population_context has_population_context This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAsJA-5zi6...#context context .
This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAsJA-5zi6...#context context http://www.w3.org/2000/01/rdf-schema#label label "Children and adolescents" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAsJA-5zi6... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAsJA-5zi6...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAsJA-5zi6... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAsJA-5zi6...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

0000-0002-7641-6446, 24 Aug 2021, 16:18:41 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial.
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-08-24T16:18:41.079Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)